Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Putting More Weight on Obesity Trials in Heart Failure.
Harrington J, Sattar N, Felker GM, Januzzi JL, Lam CSP, Pagidipati NJ, Pandey A, Van Spall HGC, McGuire DK. Harrington J, et al. Among authors: januzzi jl. Curr Heart Fail Rep. 2024 Jun;21(3):194-202. doi: 10.1007/s11897-024-00655-z. Epub 2024 Apr 15. Curr Heart Fail Rep. 2024. PMID: 38619690 Review.
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Anker SD, et al. Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904 Free article.
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16. Eur J Heart Fail. 2019. PMID: 31584231 Free article.
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.
Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL Jr, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA. Handelsman Y, et al. Among authors: januzzi jl jr. J Diabetes Complications. 2023 Feb;37(2):108389. doi: 10.1016/j.jdiacomp.2022.108389. Epub 2023 Jan 3. J Diabetes Complications. 2023. PMID: 36669322 Free article. Review.
Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.
Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL, Docherty KF, Solomon SD, McMurray JJV, Januzzi JL Jr, Vaduganathan M, Fonarow GC. Talha KM, et al. Among authors: januzzi jl jr. Eur J Heart Fail. 2023 Jul;25(7):999-1009. doi: 10.1002/ejhf.2864. Epub 2023 Apr 24. Eur J Heart Fail. 2023. PMID: 37062865
Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Myhre PL, Liu Y, Kulac IJ, Claggett BL, Prescott MF, Felker GM, Butler J, Piña IL, Rouleau JL, Zile MR, McMurray JJV, Ward JH, Solomon SD, Januzzi JL. Myhre PL, et al. Among authors: januzzi jl. Eur J Heart Fail. 2023 Aug;25(8):1396-1405. doi: 10.1002/ejhf.2957. Epub 2023 Jul 11. Eur J Heart Fail. 2023. PMID: 37401523 Free article. Clinical Trial.
826 results